Zydus Wellness Stock Surges 10% on Motilal Oswal's 'Buy' Call, 35% Upside Forecast

s shares soared nearly 10% over two days, fueled by a bullish initiation from Motilal Oswal, which slapped a 'Buy' rating on the diversified health and nutrition player and projected up to 35% gains. The stock touched an intraday peak of ₹483.40 on Thursday—up over 6% at one point—before settling 2% higher at ₹465.50. This follows a December 30 close of ₹424, amplifying the momentum from the brokerage's report. In its December 31 note, Motilal Oswal set a target price of ₹575, citing Zydus's strong foothold in consumer wellness segments. The firm's portfolio shines with market-leading brands like sugar substitute Sugar Free, glucose powder Glucon-D, skincare line Everyuth, functional spreads Nutralite, prickly-heat powder Nycil, and nutritional drink Complan. "Zydus's diversified offerings and category dominance position it for robust growth in the expanding wellness market," the report highlighted, underscoring the company's resilience amid rising health consciousness in India. Investors are eyeing sustained rallies as the stock reclaims key levels.